---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-086674"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2026-07-24T20:51:25+00:00"
generated_at: "2026-07-24T20:52:06.136269+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma receives Nasdaq notice of non-compliance with Bid Price Rule; Panel to decide on continued listing

## Summary
- Received Nasdaq notice on July 20, 2026 that it has not regained compliance with $1 minimum bid price rule and is not eligible for second 180-day extension.
- Nasdaq Hearings Panel will consider this deficiency in decision on continued listing; company must submit written view by July 27, 2026.
- Company filed definitive proxy for August 3, 2026 annual meeting to authorize reverse stock split, a potential cure for bid price deficiency.
- No assurance that Panel will grant additional time or that company will regain compliance with Nasdaq listing rules.

## SEC filing metadata
- accession: 0001104659-26-086674
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2026-07-24T20:51:25+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465926086674/0001104659-26-086674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465926086674/tm2621298d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-086674
- JSON: https://secwatch.observer/filing/0001104659-26-086674.json
- Plain text: https://secwatch.observer/filing/0001104659-26-086674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.